Bulk Pharmaceutical API Sources for RAYALDEE

Bulk Pharmaceutical API Sources for RAYALDEE

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		H4014_SIGMA
Sigma-Aldrich		17938_SIGMA
Molport		MolPort-003-927-271
BioChemPartner		BCPP000306
BioChemPartner		BCP9000472
AKos Consulting & Solutions		AKOS015965097
MedChemexpress MCE		HY-32351

Rayaldee API Sourcing Analysis

Last updated: February 19, 2026

This report details bulk active pharmaceutical ingredient (API) sourcing considerations for Rayaldee (calcium acetate and cholecalciferol). The analysis focuses on global manufacturing capabilities, regulatory landscapes, and potential supply chain risks associated with the API components.

What is Rayaldee and Its API Components?

Rayaldee is an extended-release formulation containing two active pharmaceutical ingredients: calcium acetate and cholecalciferol (Vitamin D3). It is indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) who are not on dialysis. The drug's extended-release mechanism is critical to its therapeutic profile, requiring precise API manufacturing and formulation.

• Calcium Acetate: A salt of calcium and acetic acid. It acts as a phosphate binder, reducing phosphorus absorption in the gastrointestinal tract of patients with CKD.
• Cholecalciferol (Vitamin D3): A form of vitamin D. In SHPT, it helps regulate calcium and phosphate levels and can suppress parathyroid hormone (PTH) synthesis.

Global API Manufacturing Landscape for Calcium Acetate

Calcium acetate is a widely available and produced chemical compound. Its primary uses extend beyond pharmaceuticals, including food additives and industrial applications. This broad market contributes to a robust global supply chain.

Key Manufacturing Regions and Suppliers

• China: Dominates global production of many chemical APIs, including calcium acetate, due to lower manufacturing costs and established chemical industry infrastructure. Numerous manufacturers offer pharmaceutical-grade calcium acetate.
• India: A significant player in API manufacturing, with a strong focus on regulatory compliance and Good Manufacturing Practices (GMP). Indian suppliers are a key source for pharmaceutical-grade calcium acetate.
• United States: Domestic production exists, though often at a higher cost compared to Asian manufacturers. U.S. suppliers cater to markets prioritizing domestic sourcing and stringent quality control.
• European Union: Several manufacturers in countries like Germany and Italy produce pharmaceutical-grade calcium acetate. These suppliers often emphasize high purity and adherence to European Medicines Agency (EMA) standards.

Supplier Considerations

• GMP Compliance: Essential for pharmaceutical use. Manufacturers must adhere to ICH Q7 guidelines for API GMP.
• Regulatory Filings: Availability of Drug Master Files (DMFs) or Certificates of Suitability (CEPs) simplifies regulatory approval for finished drug products.
• Quality Control: Robust testing for purity, heavy metals, and residual solvents is paramount.
• Supply Chain Stability: Diversification of suppliers is crucial to mitigate risks related to geopolitical events, trade disputes, or localized production disruptions.

Global API Manufacturing Landscape for Cholecalciferol (Vitamin D3)

Cholecalciferol manufacturing is more specialized than calcium acetate due to its origin as a biological derivative and the complexities of its synthesis and purification.

Key Manufacturing Regions and Suppliers

• China: A leading global producer of cholecalciferol. Chinese manufacturers, particularly those with established fermentation and synthesis capabilities, supply a significant portion of the global API market.
• India: Possesses significant capabilities in vitamin production, including cholecalciferol. Indian suppliers are a reliable source, often with strong regulatory track records.
• Europe: Manufacturers in countries like Denmark and Germany are also key players, often focusing on high-purity grades and specialized formulations.
• United States: Limited primary manufacturing of cholecalciferol API exists domestically, with more focus on formulation and distribution.

Supplier Considerations

• Source Material: Cholecalciferol is often derived from lanolin (wool grease). The sourcing and quality of this raw material are critical.
• Synthesis and Purification: The multi-step synthesis and purification processes require specialized expertise and controlled environments to ensure API purity and stability.
• Stability: Vitamin D3 is sensitive to light, oxygen, and heat. API manufacturers must demonstrate robust stability data and appropriate packaging solutions.
• Regulatory Approvals: DMFs filed with regulatory agencies (FDA, EMA) are standard for pharmaceutical-grade cholecalciferol.
• Potency and Impurities: Strict control over potency and the identification and quantification of process-related impurities and degradation products are vital.

Regulatory Requirements for Rayaldee API Sourcing

Sourcing APIs for a marketed drug like Rayaldee necessitates adherence to stringent regulatory frameworks designed to ensure patient safety and drug efficacy.

Key Regulatory Bodies and Guidelines

• U.S. Food and Drug Administration (FDA): Regulates APIs through the Center for Drug Evaluation and Research (CDER). Manufacturers must comply with Current Good Manufacturing Practices (CGMP) as defined in 21 CFR Parts 210 and 211. API suppliers should have a history of successful FDA inspections.
• European Medicines Agency (EMA): Oversees API quality and GMP compliance in the EU. Manufacturers typically need a Certificate of Suitability (CEP) issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) or have their facilities inspected and approved by EU national competent authorities.
• International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH): Provides guidelines that are widely adopted by regulatory agencies. Key guidelines include:
  • ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.
  • ICH Q10: Pharmaceutical Quality System.
  • ICH Q11: Development and Manufacture of Drug Substances.
• Other National Regulatory Agencies: Depending on the target markets for Rayaldee, compliance with regulations from agencies in Japan (PMDA), Canada (Health Canada), and other countries is necessary.

Documentation Requirements

• Drug Master File (DMF) / Active Substance Master File (ASMF): A confidential detailed document submitted to regulatory authorities by the API manufacturer, describing the manufacturing process, quality control, and stability of the API. This allows the finished drug product manufacturer to reference the API information without full disclosure from the supplier.
• Certificate of Suitability (CEP): Issued by the EDQM, demonstrating that the API complies with the European Pharmacopoeia monograph.
• Quality Agreements: Formal agreements between the API supplier and the finished drug product manufacturer outlining responsibilities for quality control, change management, and regulatory compliance.
• Certificates of Analysis (CoA): Issued for each batch of API, confirming it meets defined specifications.

Supply Chain Risk Assessment for Rayaldee API Components

The sourcing of both calcium acetate and cholecalciferol APIs presents potential supply chain vulnerabilities that require proactive management.

Risks Associated with Calcium Acetate

• Commoditization: As a widely produced chemical, pricing can be highly competitive, potentially leading to quality compromises if cost is the sole selection criterion.
• Geopolitical Stability: Dependence on manufacturing hubs in specific regions (e.g., China) can expose the supply chain to trade tariffs, export restrictions, or political instability.
• Raw Material Availability: While generally stable, fluctuations in the cost or availability of basic chemical precursors could impact supply.

Risks Associated with Cholecalciferol (Vitamin D3)

• Raw Material Dependence (Lanolin): The primary source of lanolin is sheep wool. Seasonal factors, animal health, agricultural policies, and global wool production levels can influence lanolin availability and price.
• Specialized Manufacturing: Fewer global manufacturers possess the specialized technology and expertise for high-purity cholecalciferol production, creating a more concentrated supply base.
• Regulatory Scrutiny: APIs derived from animal sources can sometimes face increased regulatory scrutiny regarding origin, processing, and potential contaminants (e.g., prions, although less relevant for Vitamin D3).
• Stability Issues: Inadequate handling, packaging, or storage during transit can lead to degradation, impacting API potency and efficacy.

General Supply Chain Risks

• Single-Source Dependency: Relying on a single API supplier for either component significantly increases risk. Dual-sourcing or developing backup suppliers is a critical mitigation strategy.
• Quality Deviations: Batch-to-batch variability or unexpected quality issues can halt production and necessitate extensive investigations and potential recalls.
• Logistics and Transportation: Disruptions in global shipping, port congestion, or temperature-controlled transport failures can delay shipments and compromise API integrity.
• Intellectual Property and Counterfeiting: While API sourcing focuses on generic supply, vigilance against counterfeit APIs or IP infringements in manufacturing processes is always a consideration.

Strategies for Secure API Sourcing

To ensure a reliable and compliant supply of APIs for Rayaldee, pharmaceutical manufacturers should implement the following strategies.

Supplier Qualification and Auditing

• Conduct thorough due diligence on potential API suppliers, including site audits to assess GMP compliance, quality management systems, and manufacturing capabilities.
• Verify regulatory compliance, including successful FDA, EMA, or other relevant authority inspections.
• Review supplier's historical performance, including quality metrics, on-time delivery rates, and responsiveness to issues.

Dual-Sourcing and Geographic Diversification

• Establish relationships with at least two qualified API suppliers for each component.
• Diversify supplier locations to mitigate risks associated with regional disruptions. For example, sourcing calcium acetate from both China and India, and cholecalciferol from China and Europe.

Robust Quality Agreements and Specifications

• Develop comprehensive Quality Agreements that clearly define roles, responsibilities, and expectations for API quality, change control, and regulatory reporting.
• Establish stringent API specifications that encompass purity, impurity profiles, physical characteristics, and stability requirements, aligned with regulatory filings.

Supply Chain Monitoring and Risk Management

• Implement a continuous monitoring program for geopolitical events, regulatory changes, and supplier performance.
• Develop contingency plans for supply disruptions, including inventory management strategies and pre-qualified backup suppliers.
• Regularly review the API supply chain's resilience and adapt strategies as needed.

Technical Expertise and Partnership

• Maintain strong in-house technical expertise in API chemistry, manufacturing, and quality control.
• Foster collaborative partnerships with API suppliers, promoting transparency and open communication.

Conclusion

The sourcing of bulk APIs for Rayaldee, specifically calcium acetate and cholecalciferol, requires a strategic approach focused on quality, regulatory compliance, and supply chain resilience. While calcium acetate is a widely available commodity, cholecalciferol presents a more specialized manufacturing landscape. Global manufacturers in China, India, and Europe are key sources for both APIs. Pharmaceutical companies must prioritize suppliers with robust GMP compliance, a history of regulatory success, and a commitment to quality. Implementing dual-sourcing strategies, thorough supplier qualification, and proactive risk management are critical to ensuring a stable and compliant API supply chain for Rayaldee.

---

Key Takeaways

• Rayaldee's APIs, calcium acetate and cholecalciferol, are manufactured globally, with China and India being dominant producers for both.
• Calcium acetate is a widely produced chemical, while cholecalciferol manufacturing is more specialized, requiring specific technical expertise and raw material sourcing.
• Regulatory compliance, including adherence to ICH Q7 GMP guidelines and the availability of DMFs/CEPs, is non-negotiable for API suppliers.
• Supply chain risks for calcium acetate include commodity pricing pressures and geopolitical factors, while cholecalciferol risks involve raw material dependency (lanolin) and a more concentrated supplier base.
• Secure API sourcing necessitates dual-sourcing, geographic diversification, robust quality agreements, and continuous supply chain monitoring.

---

Frequently Asked Questions

1. What are the primary regulatory hurdles for API suppliers to provide material for Rayaldee? Suppliers must demonstrate compliance with Current Good Manufacturing Practices (CGMP) as per ICH Q7. This includes robust quality management systems, validated manufacturing processes, and comprehensive impurity profiling. Submission of Drug Master Files (DMFs) or Certificates of Suitability (CEPs) to relevant health authorities (FDA, EMA) is also a standard requirement for pharmaceutical-grade APIs.

2. How does the extended-release formulation of Rayaldee impact API sourcing requirements? The extended-release formulation requires API manufacturers to provide material with consistent particle size distribution, crystal form, and purity to ensure predictable dissolution and release profiles. Manufacturers must also demonstrate stability of the API under conditions that support the drug product's shelf life.

3. What is the typical lead time for securing a new API supplier for a drug like Rayaldee? Establishing a new API supplier typically involves a qualification process that can take 6 to 12 months. This period includes initial supplier assessment, site audits, sample testing, process validation, and regulatory documentation review. For a complex API like cholecalciferol, this timeline could extend further.

4. What are the potential consequences of sourcing from non-GMP compliant suppliers? Sourcing from non-GMP compliant suppliers poses significant risks, including inconsistent API quality, introduction of impurities, potential patient safety issues, and regulatory non-compliance. Regulatory agencies may reject drug products that use APIs from unapproved or non-compliant sources, leading to market withdrawal and severe financial penalties.

5. How is the sourcing of the Vitamin D3 precursor, lanolin, managed to ensure a stable supply? The stability of lanolin sourcing depends on the global sheep population, wool harvesting cycles, and demand from various industries. API manufacturers of cholecalciferol often work with multiple lanolin suppliers and may maintain buffer stocks of lanolin or the intermediate sterols to mitigate potential supply chain disruptions. Geographical diversification of lanolin sourcing can also reduce risk.

---

Citations

[1] U.S. Food and Drug Administration. (n.d.). Guidance for Industry: ANDAs — Reporting Batch Records. Retrieved from [FDA website] [2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP). Retrieved from [EDQM website] [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1999). ICH Harmonised Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7. Retrieved from [ICH website] [4] World Health Organization. (2010). Good manufacturing practices for pharmaceutical products: main principles. WHO Technical Report Series, No. 961, Annex 4. [5] U.S. Food and Drug Administration. (2009). Guidance for Industry: Changes to an Approved Application. Retrieved from [FDA website]